CIK 0001754068 · Non-accelerated filer<br>Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831971007
- Phone
- 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-27 | Vandekop Amy O'Leary VP, Corporate Controller | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2026-08-01 | KEATING LAURIE Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-07-20 | Bayko Liisa Ann Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2026-06-03 | Jovan-Embiricos Morana Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2026-06-03 | Ferrara Napoleone Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2026-06-03 | Hallal David Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2026-06-03 | AKKARAJU SRINIVAS Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2026-06-03 | Dybbs Michael Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2026-06-03 | ADAMIS ANTHONY P Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2026-06-03 | PATTERSON LEONE D Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2026-05-20 | AKKARAJU SRINIVAS Director | Purchase | +244,300 | $4.83 | $1.2M | 2,224,147 |
| 2026-05-20 | AKKARAJU SRINIVAS Director | Other disposition | −66,906 | 10,657,028 | ||
| 2026-05-20 | AKKARAJU SRINIVAS Director | Other acquisition | +14,937 | 14,937 | ||
| 2026-05-20 | AKKARAJU SRINIVAS Director | Other acquisition | +4,471 | 19,408 | ||
| 2026-03-20 | Hagen Brett R Chief Accounting Officer | Sale | −1,915 | $6.72 | $13K | 0 |
| 2026-03-19 | Hagen Brett R Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +60,800 | 60,800 | ||
| 2026-03-19 | Oxtoby Andrew See Remarks | Grant or award · Stock Option (Right to Buy) | +222,000 | 222,000 | ||
| 2026-03-19 | Gall Matthew Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2026-03-19 | Feinsod Matthew Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2025-12-22 | AKKARAJU SRINIVAS Director | Grant or award | +1,500,000 | $10.00 | $15.0M | 1,500,000 |
Page 1 of 7 · 122 trades